Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II HIV-1 DNA + recombinant vaccinia vaccine in low- and high-risk adults
CTR20130985Phase 2Completed
- Sponsor
- CNAIDS
- Start
- Nov 2014
- Modality
- Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of HIV-1 DNA pGP140, HIV-1 DNA pGPNEF, recombinant Tiantan vaccinia HIV vaccine in human immunodeficiency virus infection (HIV), sponsored by CNAIDS. Started Nov 2014; status: completed.
02
Drugs
HIV-1 DNA pGP140HIV-1 DNA pGPNEFrecombinant Tiantan vaccinia HIV vaccine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on CTR20130985.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20130985.